Connect
← Return to New research on length of ADT therapy for patients with RT
Discussion
New research on length of ADT therapy for patients with RT
Prostate Cancer | Last Active: Dec 17 10:11am | Replies (27)Comment receiving replies
The clinical trials they base the standard of care therapies on have to be based on old data because prostate cancer develops so slowly. I haven't tried to find out what these ideas about intermittent ADT are based on at this point, as its only been two weeks since I started taking Orgovyx.
So far I've been looking for info on what is known as to what length of ADT can benefit a GGIII, cT3b, SVI involvement, localized high risk prostate cancer case (i.e. mine), and what benefit that is.
It looks to me like the best approach for me is to see if I can get a definitive therapy that studies show that taking ADT for longer than 6 months has no benefit, i.e. EBRT + BT boost.
Replies to "The clinical trials they base the standard of care therapies on have to be based on..."
Connect
@climateguy That study you posted by Dr Stone made it pretty clear that there is no statistical difference in outcomes between 6 months of ADT or 30 when used with high boost brachy/EBRT.
My approach would be to agree with the RO to do 6 months of Orgovyx and then test the PSA every month for 6 months….then every three months for a year or two.
It’s totally reasonable and remember, it’s YOUR decision.
You seem like a pretty sharp guy and I would assume that you will be all over this so there will never be any big surprises.
Phil